Cornerstone Pharmaceuticals Inc. (Cornerstone)

Oncology Corporate Profile

HQ Location

1 Duncan Drive
Cranbury, NJ 8512

Company Description

Cornerstone Pharmaceuticals is a privately held pharmaceutical company uniquely focused on the discovery and development of innovative cancer therapies that exploit the metabolic pathways that are common to different cancer types but different from normal cells and tissues. The Company believes that their approach, i.e. understanding and addressing what is similar to cancer types rather than the differences of each, offers the best opportunity to have a profound impact on the clinical treatment of a variety of cancers.

Website: http://www.cornerstonepharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CPI-613altered energy metabolism-directed (AEMD) compoundAcute Myelogenous Leukemia (AML)III
CPI-613altered energy metabolism-directed (AEMD) compoundMyelodysplastic Syndrome (MDS)III
CPI-613altered energy metabolism-directed (AEMD) compoundVarious cancer typesIII
CPI-613altered energy metabolism-directed (AEMD) compoundPancreatic cancerII
CPI-613altered energy metabolism-directed (AEMD) compoundVarious cancer typesII
CPI-613altered energy metabolism-directed (AEMD) compoundAcute Myelogenous Leukemia (AML)I
CPI-613altered energy metabolism-directed (AEMD) compoundB-cell Non-Hodgkin's Lymphoma (NHL)I
CPI-613altered energy metabolism-directed (AEMD) compoundColorectal cancerI
CPI-613altered energy metabolism-directed (AEMD) compoundHodgkin's LymphomaI
CPI-613altered energy metabolism-directed (AEMD) compoundPancreatic cancerI
CPI-613altered energy metabolism-directed (AEMD) compoundT- cell Non-Hodgkin's Lymphoma (NHL)I
EmPACnanoemulsion-based drug delivery systemVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.cornerstonepharma.com

Recent News Headlines

Phase I Trial Data for Cornerstone Pharmaceuticals' CPI-613 in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in Metastatic Pancreatic Adenocarcinoma to Be Presented at ASCO GI

1/26/2016 05:41 pm

(Yahoo! Finance) Jan 25, 2016 - Cornerstone Pharmaceuticals, Inc. today announced that data from the Phase I clinical trial evaluating CPI-613 in combination with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) to treat metastatic pancreatic adenocarcinoma was presented at the Annual Gastrointestinal Cancers Symposium, held by the American Society of Clinical Oncology (ASCO) in San Francisco, California on Friday, January 22, 2016.

Many Young Cancer Patients May Have Limited Awareness of Fertility Preservation Options

7/27/2015 11:04 am

(Wiley) July 27, 2015 - A new study points to the need for increased awareness of fertility preservation options for young patients with cancer.

Study: Gene Therapy Superior to Half-Matched Transplant for Children with “Bubble Boy Disease”

4/14/2015 12:02 pm

(ASH) Apr 13, 2015 - New research published online today in Blood, the Journal of the American Society of Hematology, reports that children with “bubble boy disease” who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor.

Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 For the Treatment of B-Cell Non-Hodgkin Lymphoma

12/5/2014 05:35 pm

(StreetInsider) Dec 5, 2014 - Cornerstone Pharmaceuticals, Inc. today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients With Locally Advanced or Metastatic Pancreatic Cancer

10/31/2013 04:20 pm

(Yahoo! Finance) Oct 31, 2013 - Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 for the treatment of patients with locally advanced or metastatic pancreatic cancer.

Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients With Locally Advanced or Metastatic Pancreatic Cancer

10/31/2013 11:02 am

(Yahoo! Finance) Oct 31, 2013 - Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 for the treatment of patients with locally advanced or metastatic pancreatic cancer.

Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell Lung Cancer

10/24/2013 04:58 pm

(iStockAnalyst) Oct 24, 2013 - Cornerstone Pharmaceuticals, Inc. today announced the initiation of a pilot Phase II clinical trial of CPI-613 for the treatment of relapsed or refractory small cell lung cancer (SCLC) patients.

Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell Lung Cancer

10/24/2013 11:05 am

(iStockAnalyst) Oct 24, 2013 - Cornerstone Pharmaceuticals, Inc. today announced the initiation of a pilot Phase II clinical trial of CPI-613 for the treatment of relapsed or refractory small cell lung cancer (SCLC) patients.

Analysis of Little-Explored Regions of Genome Reveals Dozens of Cancer Triggers

10/4/2013 11:00 am

(Yale News) Oct 3, 2013 - A massive data analysis of natural genetic variants in humans and variants in cancer tumors has implicated dozens of mutations in the development of breast and prostate cancer, a Yale-led team has found.

Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome

10/3/2013 05:14 pm

(Yahoo! Finance) Oct 3, 2013 - Cornerstone Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613, the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS).

Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome

10/3/2013 12:01 pm

(Yahoo! Finance) Oct 3, 2013 - Cornerstone Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613, the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS).

Researchers Find Two New Methods to Determine ALK Status

7/2/2013 11:04 am

(IASLC) July 1, 2013 - Tests continue trend in personalized medicine for lung cancer patients.

Cornerstone Drug for Low Salt Rejected by U.S. Panel

9/13/2012 05:23 pm

(CNBC/Reuters) Sept 13, 2012 - Cornerstone Therapeutics Inc failed to win a U.S. panel's support on Thursday for a drug that treats low sodium levels in the blood.

Cornerstone Drug for Low Salt Rejected by U.S. Panel

9/13/2012 12:02 pm

(CNBC/Reuters) Sept 13, 2012 - Cornerstone Therapeutics Inc failed to win a U.S. panel's support on Thursday for a drug that treats low sodium levels in the blood.

University of Colorado Cancer Center Welcomes 9 New Members

8/2/2012 11:05 am

(UCCC blog) Aug 1, 2012 - The University of Colordo Cancer Center is excited to welcome the following new members.

Removing Colon Polyps Tied to Lower Cancer Risk

7/25/2012 11:05 am

(Chicago Tribune/Reuters Health) July 24, 2012 - People who have had risky, possibly pre-cancerous polyps removed from their colon may be able to wait up to five years until their next colonoscopy, a new study from Germany suggests.

A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting

6/29/2012 11:00 am

(Marketwatch) June 29, 2012 - A.P. Pharma, Inc., a specialty pharmaceutical company, today announced additional data from the Company's Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV).

VEGF-C and VEGF-D Identified as Biomarkers for Avastin Resistance in Colorectal Cancer Patients

6/7/2011 02:02 pm

(DailyMarkets) June 6, 2011 - Circadian Technologies Limited announced today the presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago USA associating resistance to Avastin with increases in plasma VEGF-C and D concentrations.